Can-Fite BioPharma (CANF) Soars on 9-Year Liver Cancer Survival Breakthrough with Namodenoson – November 18, 2025

Can-Fite BioPharma (CANF) Soars on 9-Year Liver Cancer Survival Breakthrough with Namodenoson – November 18, 2025

Small-cap Israeli biotech rallies after reporting a decade-long cancer‑free outcome in advanced hepatocellular carcinoma and launching enrollment in a pivotal Phase III trial. Shares of Can-Fite BioPharma Ltd. (NYSE American: CANF, TASE: CANF) jumped on Tuesday after the company reported
Medtronic (MDT) Soars as Q2 FY26 Earnings Beat Expectations and 2026 Outlook Is Raised on Pulsed Field Ablation Strength

Medtronic (MDT) Soars as Q2 FY26 Earnings Beat Expectations and 2026 Outlook Is Raised on Pulsed Field Ablation Strength

Published: November 18, 2025 Medtronic plc (NYSE: MDT) is back in the spotlight today after reporting stronger‑than‑expected results for the second quarter of fiscal 2026 and raising its full‑year outlook. The medical technology giant delivered solid revenue and earnings growth,
Go toTop